SCHEMBL4499115

SCHEMBL4499115

O=C(O)C1CNCC(NS(=O)(=O)c2cccc3ccccc23)C1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
REN P00797 3/20 0.44
TSHR P16473 1/20 0.44
SLC1A3 P43003 1/20 0.43
SLC1A2 P43004 1/20 0.43
SLC1A1 P43005 1/20 0.43
CCR8 P51685 2/20 0.42
SLC6A1 P30531 1/20 0.41
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
NPY5R Q15761 3/20 0.41
HCRTR1 O43613 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
PFKFB3 Q16875 1/20 0.40
STK33 Q9BYT3 1/20 0.40
GBA1 P04062 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4499118 1.00 REN (0.44) RENTSHRSLC1A3SLC1A2SLC1A1
SCHEMBL1913202 0.84 REN (0.66) RENTSHRSLC1A3SLC1A2SLC1A1
SCHEMBL4504905 0.84 ALDH1A1 (0.56) RENSLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL4504903 0.84 ALDH1A1 (0.56) RENSLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL4504762 0.82 REN (0.46) RENALDH1A1HTT
SCHEMBL4504759 0.82 REN (0.46) RENALDH1A1HTT
SCHEMBL4498089 0.81 REN (0.49) RENTSHRALDH1A1STK33
SCHEMBL4498092 0.81 REN (0.49) RENTSHRALDH1A1STK33
SCHEMBL4490896 0.81 ALDH1A1 (0.59) TSHRALDH1A1HTTHDAC1
SCHEMBL4490892 0.81 ALDH1A1 (0.59) TSHRALDH1A1HTTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 REN 1/4885TSHR 933/4885SLC1A3 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.